<DOC>
	<DOCNO>NCT00928642</DOCNO>
	<brief_summary>This study evaluate efficacy tolerability combination Gleevec Gemzar patient ovarian cancer , progress receive least one prior chemotherapy treatment . Gleevec oral chemotherapy drug use study Gemzar IV chemotherapy drug use . Participation treatment portion study continue long patient 's tumor shrink remain stable long patient able tolerate study drug . The follow-up portion study last 5 year .</brief_summary>
	<brief_title>Gleevec Gemzar Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description>Each 21 day period consider cycle . Disease status assess Cancer Antigen ( CA ) -125 prior start new cycle assessment measurable diseased either CT MRI every 6 week . Treatment continue disease progression , unacceptable toxicity , patient elect withdraw study . All patient follow disease progression study withdraw . In addition , follow disease progression , patient monitor delayed toxicity survival period 5 year , unless consent withdrawn .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients 18 year age great Histologically document diagnosis ovarian cancer primary peritoneal cancer . Histological subtypes include : mucinous tumor , serous tumor , endometrioid tumor , histology include clear cell undifferentiated epithelial tumor . At least one measurable site disease ( defined Southwestern Oncology Group Solid Tumor Response Criteria ) response assessment criterion , appropriate . Patients must relapse receive least one prior platinumbased chemotherapy . Performance status 0 , 1 , 2 , ( ECOG ) Adequate end organ function : Total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 UNL , creatinine &lt; 1.5 x UNL , ANC &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L . Patients likely ovary remove time initial surgery . If subject childbearing potential time entry , must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Subjects reproductive potential must agree employ effective barrier method birth control throughout study 3 month follow discontinuation study drug . Written , voluntary inform consent . Patients must eligible care military medical treatment facility . Patient receive prior treatment Gemzar . Patient receive investigational agent within 28 day first day study drug dose . Patient &lt; 5 year free another primary malignancy except : primary malignancy neither currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . Patients pregnant breastfeeding . Patient severe and/or uncontrolled medical disease ( , e . uncontrolled diabetes , uncontrolled chronic renal disease , active uncontrolled infection ) . Patient know untreated progressive brain metastasis . Patient know chronic liver disease ( i.e . chronic active hepatitis , cirrhosis . Patient known diagnosis human immunodeficiency virus ( HIV infection ) . Patient receive chemotherapy within 4 week ( 6 week nitrosourea mitomycinC ) prior study entry , unless disease rapidly progressing.. Patient previously receive radiotherapy great equal 25 % bone marrow . Patient major surgery within 2 week prior study entry . Patient significant history noncompliance medical regimen inability grant reliable informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ovarian</keyword>
	<keyword>cancer</keyword>
	<keyword>peritoneal</keyword>
	<keyword>endometrioid</keyword>
	<keyword>mucinous</keyword>
	<keyword>serous</keyword>
	<keyword>clear cell</keyword>
</DOC>